基于网络药理学分析探讨胃糜舒治疗慢性萎缩性胃炎肝胃不和型的相关作用机制  

Exploring the Mechanism of Action of Weimishu in the Treatment of Chronic Atrophic Gastritis with Hepatogastric Disharmony Based on Network Pharmacological Analysis

作　　者：张倩玉 曹生海 

机构地区：[1]青海大学医学院,青海 西宁 [2]青海省中医院脾胃科,青海 西宁

出　　处：《临床个性化医学》2024年第4期1859-1868,共10页Journal of Clinical Personalized Medicine

摘　　要：目的:基于网络药理学分析探讨胃糜舒治疗慢性萎缩性胃炎肝胃不和型的相关作用机制,为后续实验提供参考。方法:通过中药系统药理数据库与分析平台(Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform, TCMSP)和Herb (http://herb.ac.cn/)进行药物的活性成分的筛选,根据药代动力学特征ADME,将化合物SMLIE号导入SwissTargetPrediction数据库筛选药物的作用靶点。通过GeneCards、OMIM数据库,得到目标靶点基因,利用String平台进行蛋白质相互作用分析,构建PPI网络互作图。采用DAVID数据库平台分析“药物–成分–靶点”及其参与的生物过程及通路。结果:胃糜舒的核心活性成分为豆甾醇、异鼠李素、山萘酚、槲皮素、β-谷甾醇,主要作用于IL-17信号通路、TNF信号通路、p53信号通路、NF-κB信号通路和JAK/STAT信号通路。结论:本研究对胃糜舒治疗慢性萎缩性胃炎肝胃不和型的作用机制进行了初步网络验证,为后续实验研究提供参考。Objective: This paper aims to investigate the mechanism of action of Weimishu in the treatment of chronic atrophic gastritis with hepatogastric disharmony based on network pharmacological analysis, so as to provide reference for follow-up experiments. Methods: The active ingredients of the drugs were screened through the Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform (TCMSP) and Herb (http://herb.ac.cn/), and the compounds SMLIE were selected according to the pharmacokinetic characteristics of ADME The target of action of the drug was screened into the SwissTargetPrediction database. Through the GeneCards and OMIM databases, the target genes were obtained, and the String platform was used for protein-protein interaction analysis to construct the PPI network interaction map. The DAVID database platform was used to analyze the “drug-component-target” and the biological processes and pathways involved in it. Results: The cor

关 键 词：胃糜舒 NF-ΚB信号通路 JAK/STAT信号通路 

分 类 号：R73[医药卫生—肿瘤]